Table 1 Overview of the study design to evaluate the preventive efficacy of Bravecto® Plus spot-on solution at the minimum recommended dose (2.0 mg moxidectin/kg BW + 40 mg fluralaner/kg) compared to placebo treatment (0.9% saline solution)
Group | No. of cats | Treatment (study day) | Infection with 300 Aelurostrongylus abstrusus L3 (study day) | Necropsy (study day) | |
|---|---|---|---|---|---|
1 | 8 | 0 | Bravecto® Plus spot-on solution | 84 | 131–134 |
28 | Placebo | ||||
56 | Placebo | ||||
2 | 8 | 0 | Placebo | ||
28 | Bravecto® Plus spot-on solution | ||||
56 | Placebo | ||||
3 | 7 | 0 | Placebo | ||
28 | Placebo | ||||
56 | Bravecto® Plus spot-on solution | ||||
4 | 8 | 0 | Placebo | ||
28 | Placebo | ||||
56 | Placebo | ||||